July 19, 2013
/PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today provided further updates on the business development of its flagship product: Gingko Mihuan Oral Liquid (GMOL) with the SFDA approval number: H20013079.
GMOL is a prescription medicine that targets cardiovascular indications such as strokes, coronary heart diseases, angina as well as reduces the risks of age-related cardiovascular ailments. Additional information regarding GMOL can also be accessed at the official website of SFDA at
, (Chinese version) or
, GMOL was awarded Provincial Essential Drug List (PEDL) status at
, one of the major provinces of
with population over 100 million (
). This is the fifth province that awarded PEDL status to TPI's GMOL after its PEDL listings at
City of Chongqing
(Directly Governed City, the same status as provinces). The combined population of these regions is estimated at approximately 330 million (
Under the ongoing healthcare reform, PEDL listing ensures the full coverage of the costs for the patients who use the PEDL drugs. As a result, national and provincial EDL listings could substantiate the market development for these products.
, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of
. For more information about TPI, please visit:
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.